Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 24
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Marker Therapeutics Inc
MRKR
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.9601
-0.11
-10.27%
Ult. Agg.: Oct 23, 7:50 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Marker Therapeutics Financials
Marker Therapeutics (MRKR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Marker Therapeutics Q1 EPS $(0.16) Beats $(0.18) Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 60 percent increase over losses of $(0.40) per share from
Benzinga Newsdesk
PRO
Marker Therapeutics Q4 EPS $(0.09) Beats $(0.47) Estimate, Sales $1.103M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.47) by 81.68 percent. This is a 79.29 percent increase over losses of $(0.42) per share
Benzinga Newsdesk
PRO
Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.47) by 74.74 percent. This is a 53.85 percent increase over losses of $(0.26) per share
Benzinga Newsdesk
Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings
Avi Kapoor
PRO
Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. The company reported quarterly sales of $1.926 million which beat
Benzinga Newsdesk
PRO
Marker Therapeutics Q2 2024 GAAP EPS $(0.25) Beats $(0.43) Estimate, Sales $1.17M Up From $762.66K YoY
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.43) by 41.86 percent. The company reported $1.17 million in sales this quarter. This is a
Benzinga Newsdesk
